Qvist P - Search Results

1

Biochemical markers of joint tissue turnover.

Bay-Jensen AC, Sondergaard BC, Christiansen C, Karsdal MA, Madsen SH, Qvist P. Bay-Jensen AC, et al. Among authors: qvist p. Assay Drug Dev Technol. 2010 Feb;8(1):118-24. doi: 10.1089/adt.2009.0199. Assay Drug Dev Technol. 2010. PMID: 19715454 Review.

2

Measurement of a more stable region of osteocalcin in serum by ELISA with two monoclonal antibodies.

Rosenquist C, Qvist P, Bjarnason N, Christiansen C. Rosenquist C, et al. Among authors: qvist p. Clin Chem. 1995 Oct;41(10):1439-45. Clin Chem. 1995. PMID: 7586514

3

Applications of an enzyme immunoassay for a new marker of bone resorption (CrossLaps): follow-up on hormone replacement therapy and osteoporosis risk assessment.

Bonde M, Qvist P, Fledelius C, Riis BJ, Christiansen C. Bonde M, et al. Among authors: qvist p. J Clin Endocrinol Metab. 1995 Mar;80(3):864-8. doi: 10.1210/jcem.80.3.7883844. J Clin Endocrinol Metab. 1995. PMID: 7883844 Clinical Trial.

4

Immunoassay for quantifying type I collagen degradation products in urine evaluated.

Bonde M, Qvist P, Fledelius C, Riis BJ, Christiansen C. Bonde M, et al. Among authors: qvist p. Clin Chem. 1994 Nov;40(11 Pt 1):2022-5. Clin Chem. 1994. PMID: 7955372

5

Coated-tube radioimmunoassay for C-telopeptides of type I collagen to assess bone resorption.

Bonde M, Fledelius C, Qvist P, Christiansen C. Bonde M, et al. Among authors: qvist p. Clin Chem. 1996 Oct;42(10):1639-44. Clin Chem. 1996. PMID: 8855148 Clinical Trial.

6

Development of a monoclonal antibody to urinary degradation products from the C-terminal telopeptide alpha 1 chain of type I collagen. Application in an enzyme immunoassay and comparison to CrossLaps ELISA.

Fledelius C, Kolding I, Qvist P, Bonde M, Hassager C, Reginster JY, Hejgaard J, Frøokiaer H, Christiansen C. Fledelius C, et al. Among authors: qvist p. Scand J Clin Lab Invest. 1997 Feb;57(1):73-83. doi: 10.1080/00365519709057821. Scand J Clin Lab Invest. 1997. PMID: 9127460 Clinical Trial.

7

Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 amino acid sequence of the C-telopeptide of type I collagen.

Bonde M, Garnero P, Fledelius C, Qvist P, Delmas PD, Christiansen C. Bonde M, et al. Among authors: qvist p. J Bone Miner Res. 1997 Jul;12(7):1028-34. doi: 10.1359/jbmr.1997.12.7.1028. J Bone Miner Res. 1997. PMID: 9200001 Free article.

8

Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen.

Rosenquist C, Fledelius C, Christgau S, Pedersen BJ, Bonde M, Qvist P, Christiansen C. Rosenquist C, et al. Among authors: qvist p. Clin Chem. 1998 Nov;44(11):2281-9. Clin Chem. 1998. PMID: 9799755 Clinical Trial.

9

Clinical evaluation of the Serum CrossLaps One Step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides.

Christgau S, Rosenquist C, Alexandersen P, Bjarnason NH, Ravn P, Fledelius C, Herling C, Qvist P, Christiansen C. Christgau S, et al. Among authors: qvist p. Clin Chem. 1998 Nov;44(11):2290-300. Clin Chem. 1998. PMID: 9799756 Clinical Trial.

10

Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting.

Qvist P, Christgau S, Pedersen BJ, Schlemmer A, Christiansen C. Qvist P, et al. Bone. 2002 Jul;31(1):57-61. doi: 10.1016/s8756-3282(02)00791-3. Bone. 2002. PMID: 12110413

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

157 results

Search Page